SEC Filing Summary: ADVENTRX Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 8, 2009, by ADVENTRX Pharmaceuticals, Inc. (Note: The request metadata referenced "Savara Inc," but the filing text identifies the registrant as ADVENTRX Pharmaceuticals, Inc.). The report details a registered direct public offering of securities and the entry into a material definitive agreement with a placement agent.
Key Financial Metrics and Transaction Details
- Offering Size: Approximately $2.0 million in gross proceeds.
- Securities Issued: 1,993 shares of 0% Series A Convertible Preferred Stock and warrants to purchase up to 8,116,290 shares of common stock.
- Unit Structure: Each unit consists of one share of preferred stock and a warrant to purchase approximately 4,072 shares of common stock, sold at $1,000 per unit.
- Net Proceeds: Expected to be approximately $1.7 million after deducting placement agent fees and estimated offering expenses.
- Placement Agent Fees: Approximately $139,510 (7.0% of gross proceeds) plus warrants to purchase up to 901,810 shares of common stock.
- Conversion Terms: Preferred stock is convertible at $0.1105 per share; warrants are exercisable at $0.15 per share.
- Total Dilution Potential: An aggregate of 26,152,489 shares of common stock are issuable upon conversion of the preferred stock and exercise of the warrants.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with an investor and an Engagement Letter with Rodman & Renshaw, LLC as the exclusive placement agent. The transaction is expected to close on June 12, 2009. The agreement includes covenants restricting the Company's ability to amend its charter, pay dividends, repurchase shares, issue additional equity for 60 days, or incur indebtedness without consent.
Outlook, Risks, and Contingencies
- Automatic Conversion: Preferred stock automatically converts upon a change in control.
- Redemption Triggers: The Company may be obligated to redeem the preferred stock upon material breach of contract, change in control, insolvency events, or delisting of common stock.
- Listing Requirement: The Company must use reasonable best efforts to maintain the listing of its common stock on specified U.S. securities exchanges.
- Warrant Exercise Window: Warrants are exercisable six months after issuance and expire on the fifth anniversary of the initial exercise date.
Key Facts for Investor Verification
- Verify the closing of the transaction on or around June 12, 2009, and the actual net proceeds received.
- Confirm the impact of the 26.1 million potential shares on existing shareholder dilution.
- Monitor compliance with the 60-day lock-up period on issuing additional equity or incurring debt.
- Review the Company's ability to maintain its stock exchange listing to avoid redemption obligations.
- Note that the filing text does not provide current revenue, profit, or cash flow figures; this report focuses solely on the capital raise.